Summary: Patients With HIV/HCV Coinfection
Patients With HIV/HCV Coinfection
Table. Drug Interactions Between Direct-Acting Antivirals and Antiretroviral Drugs—Recommended Regimens
Ledipasvir/ Sofosbuvir(LDV/SOF) |
Sofosbuvir/ Velpatasvir(SOF/VEL) |
Elbasvir/ Grazoprevir(ELB/GRZ) |
Glecaprevir/ Pibrentasvir(GLE/PIB) |
Sofosbuvir/ Velpatasvir/ Voxilaprevir(SOF/VEL/VOX) |
||
---|---|---|---|---|---|---|
Protease
|
Boosted Atazanavir |
A | A | |||
Boosted Darunavir |
A | A | ||||
Boosted Lopinavir |
ND, A | A | ND | |||
NNRTIs |
Doravirine |
ND | ND | ND | ||
Efavirenz |
ND | ND | ||||
Rilpivirine |
||||||
Etravirine |
ND | ND | ND | ND | ND | |
Integrase
|
Bictegravir |
ND | ND | |||
Cabotegravir |
ND | ND | ND | ND | ND | |
Cobicistat-boosted elvitegravir |
C | C | C | |||
Dolutegravir |
ND | |||||
Raltegravir |
ND | |||||
Entry
|
Fostemsavir |
ND | ND | ND | ND | ND |
Ibalizumab-uiyk |
ND | ND | ND | ND | ND | |
Maraviroc |
ND | ND | ND | ND | ND | |
NRTIs |
Abacavir |
ND | ND | ND | ||
Emtricitabine |
||||||
Lamivudine |
ND | ND | ND | |||
Tenofovir disoproxil fumarate |
B, C | B, C | C | |||
Tenofovir alafenamide |
D | D | ND | D | ||
Green indicates coadministration is safe; yellow indicates a dose change or additional monitoring is warranted; and red indicates the combination should be avoided.
ND: No data For antiretroviral agents not included in the table above, please refer to the US Department of Health and Human Services HIV treatment guidelines (https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines) and/or the University of Liverpool drug interactions website (www.hep-druginteractions.org). |
Treatment Recommendations for Patients With HIV/HCV Coinfection |
|
---|---|
RECOMMENDED | RATING |
HIV/HCV-coinfected persons should be treated and retreated the same as persons without HIV infection, after recognizing and managing interactions with antiretroviral medications (see Initial Treatment of HCV Infection and Retreatment of Persons in Whom Prior Therapy Has Failed). |
I, B |